China Approves Clinical Trial of InnoCare Bispecific Antibody ICP-B161
InnoCare Pharma announced that China’s Center for Drug Evaluation approved a clinical trial of its bispecific antibody ICP-B161, which targets TL1A and IL-23p19.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.